14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $11.01 $14.21 Friday, 3rd May 2024 IOVA stock ended at $13.63. This is 5.82% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 4.36% from a day low at $13.30 to a day high of $13.88.
90 days $7.62 $18.33
52 weeks $3.21 $18.33

Historical Iovance Biotherapeutics, Inc. prices

Date Open High Low Close Volume
Mar 28, 2024 $14.12 $15.18 $14.10 $14.82 6 055 141
Mar 27, 2024 $14.20 $14.32 $13.75 $14.10 3 789 127
Mar 26, 2024 $14.81 $15.04 $13.95 $14.05 5 005 812
Mar 25, 2024 $15.00 $15.50 $14.44 $14.53 4 523 627
Mar 22, 2024 $15.23 $15.44 $14.86 $15.02 3 643 184
Mar 21, 2024 $15.04 $15.90 $15.02 $15.36 7 134 522
Mar 20, 2024 $13.90 $15.01 $13.70 $14.93 5 805 283
Mar 19, 2024 $13.78 $14.26 $13.60 $13.90 5 130 183
Mar 18, 2024 $14.05 $14.65 $13.60 $14.03 6 434 614
Mar 15, 2024 $14.07 $14.39 $13.68 $13.91 17 211 547
Mar 14, 2024 $14.75 $14.82 $13.93 $14.21 6 854 859
Mar 13, 2024 $14.70 $15.00 $14.35 $14.73 6 305 629
Mar 12, 2024 $15.10 $15.29 $14.60 $14.72 7 121 131
Mar 11, 2024 $15.70 $15.99 $14.80 $15.10 7 918 177
Mar 08, 2024 $16.83 $17.14 $15.11 $15.70 11 418 120
Mar 07, 2024 $17.40 $17.55 $16.52 $16.62 6 220 315
Mar 06, 2024 $16.83 $17.64 $16.69 $17.16 8 157 778
Mar 05, 2024 $16.74 $17.28 $15.97 $16.49 8 624 670
Mar 04, 2024 $18.10 $18.22 $16.62 $16.96 12 272 427
Mar 01, 2024 $16.36 $17.19 $16.27 $16.79 10 945 285
Feb 29, 2024 $16.83 $17.41 $15.50 $15.91 17 213 831
Feb 28, 2024 $17.26 $18.33 $16.95 $17.43 11 217 677
Feb 27, 2024 $16.84 $17.60 $16.15 $17.47 11 179 238
Feb 26, 2024 $15.80 $17.28 $15.80 $16.60 15 631 197
Feb 23, 2024 $16.00 $16.49 $15.50 $15.77 12 622 605
Click to get the best stock tips daily for free!

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics. Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or pers... IOVA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT